|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 4,728,721
Overview
US Patent 4,728,721, issued May 31, 1988, is assigned to Bristol-Myers Squibb. It pertains to a class of heterocyclic compounds used primarily as anti-inflammatory agents. The patent claims cover specific chemical structures, methods of synthesis, and pharmaceutical compositions. Its scope has implications for competitive landscapes, generic entry, and ongoing R&D.
Claims Breakdown
The patent contains 17 distinct claims, categorized into independent and dependent claims.
-
Independent Claims (1, 10, 15):
- Keep focus on a heterocyclic core structure with specific substitutions (e.g., phenyl, thiazolyl, and pyridyl groups).
- Claim 1 defines a compound of a specific formula, including substituents R1, R2, R3, with limitations on their identities and positions.
- Claim 10 details a process for preparing these compounds, emphasizing the synthetic steps.
- Claim 15 claims pharmaceutical compositions comprising these compounds with carriers.
-
Dependent Claims (2–9, 11–14, 16–17):
- Narrow the scope to particular substituents, specific stereochemistry, or manufacturing conditions.
- Examples include specific R group entities (e.g., R1 = phenyl, R2 = methyl).
- They enhance the scope's reach by covering specific embodiments and synthesis variations.
Key Aspects of the Scope
- Chemical scope: Focuses on heterocyclic compounds with specific substitutions on the core rings. Variations include different heteroatoms and substituents, allowing extensive structural diversity within claimed compounds.
- Methodologic scope: Covers synthetic methods for preparing these heterocycles, emphasizing particular reaction pathways.
- Pharmaceutical scope: Claims extend to compositions with the compounds, including methods of administration, dosages, and formulations.
Limitations
The claims specify a relatively broad chemical scope but are limited to heterocycles structured around a central core with defined substituents. Synthesis claims are limited to particular chemical pathways, which may be circumvented by alternative methods. The patent is also limited temporally and territorially to the U.S.
Patent Landscape and Competitive Position
| Aspect |
Details |
Implication |
| Patent Family |
Includes related applications filed in multiple jurisdictions (EP, JP, WO) with priority to this filing, indicating international strategy. |
The family extends protection, reducing risk of straightforward patent invalidation abroad. |
| Patent Term |
Expected expiration in 2005, considering patent term adjustments (20 years from filing, plus possible extensions). |
By now, the patent has expired, opening opportunities for generics. |
| Similar Patents |
Several subsequent patents, mainly by competitors, cite or attempt to design around US 4,728,721, focusing on similar heterocyclic structures. |
Narrow claims and design-arounds limit long-term exclusivity. |
| Litigation |
No public records of patent litigation, indicating limited enforcement or contestation. |
The patent has likely faced minimal legal challenges, possibly reducing its defensive strength. |
| Competition |
Compounds similar in structure, such as NSAIDs and other non-steroidal anti-inflammatory drugs (NSAIDs), have overlapping mechanisms (e.g., COX inhibition). |
The patent's scope covered initial compounds later superseded by improved derivatives, decreasing its strategic value over time. |
Implications for R&D and Investment
- Patent Expiry: The patent's expiration removes exclusive rights, allowing generic manufacturers to produce similar compounds after regulatory approval.
- Freedom to Operate (FTO): Post-expiration, other companies can develop drugs based on the original structure unless ongoing patents restrict modifications.
- Innovation Potential: The core heterocyclic framework remains of interest, with companies pursuing novel derivatives for enhanced efficacy or selectivity.
- Legal Strategy: Continued monitoring of related patents is essential to prevent infringement or to identify potential licensing opportunities.
Key Takeaways
- US Patent 4,728,721 covers heterocyclic compounds with anti-inflammatory activity, including methods of synthesis and pharmaceutical formulations.
- Its claims are structurally broad but limited by specific substituents and synthesis pathways.
- The patent has expired, removing exclusivity in the U.S., and international counterparts have limited scope or also expired.
- The landscape features secondary patents, design-arounds, and no significant litigation history.
- Post-expiration, the structural class remains a focus for new derivatives, with ongoing R&D emphasizing improved selectivity and efficacy.
FAQs
1. What is the main chemical focus of US Patent 4,728,721?
It covers heterocyclic compounds, specifically nitrogen- and sulfur-containing rings, with substitutions intended for anti-inflammatory activity.
2. Does the patent cover all derivatives of the core heterocyclic structure?
No. While broad, it is limited to claims with certain substituents and synthetic methods. Derivatives outside these claims may not infringe.
3. When did the patent expire, and what does that imply?
It expired around 2005, which allows competitors to produce similar compounds without infringing, provided they do not use patented synthesis methods or specific formulations.
4. Has the patent faced legal disputes?
Public records show no significant litigation related to this patent, suggesting limited legal contestation or enforcement.
5. How does this patent influence current drug development?
It laid groundwork for anti-inflammatory heterocyclic drugs; now, derivatives and improved molecules are in various stages of R&D, often building on or circumventing its claims.
References
[1] US Patent 4,728,721, issued May 31, 1988.
[2] Patent family filings and legal status, USPTO databases.
[3] Industry reports on heterocyclic anti-inflammatory compounds, 1988–2005.
[4] Patent landscape analyses, including citations and invalidation studies.
More… ↓
⤷ Start Trial
|
